EC Number | Application | Comment | Organism |
---|---|---|---|
7.4.2.8 | drug development | the enzyme is a chemotherapeutic target for small-molecule ATPase inhibitors | Burkholderia pseudomallei |
7.4.2.8 | pharmacology | the enzyme is a chemotherapeutic target for small-molecule ATPase inhibitors | Burkholderia pseudomallei |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
7.4.2.8 | additional information | generation of a bsaS deletion mutant, the bsaS deletion mutant is highly attenuated for virulence in BALB/c mice | Burkholderia pseudomallei |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
7.4.2.8 | ATPase inhibitor compound 939 | - |
Burkholderia pseudomallei |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
7.4.2.8 | Burkholderia pseudomallei | Q63K25 | gene bsaS | - |
7.4.2.8 | Burkholderia pseudomallei K96243 | Q63K25 | gene bsaS | - |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
7.4.2.8 | BsaS | - |
Burkholderia pseudomallei |
7.4.2.8 | More | cf. EC 3.6.3.14 | Burkholderia pseudomallei |
7.4.2.8 | TTSS ATPase | - |
Burkholderia pseudomallei |
7.4.2.8 | type III secretion system cluster 3 ATPase | - |
Burkholderia pseudomallei |
EC Number | General Information | Comment | Organism |
---|---|---|---|
7.4.2.8 | malfunction | loss of enzyme BsaS function either via direct genetic inactivation or treatment with the inhibitor compound 939 results in increased susceptibility of Burkholderia pseudomallei to microtubule-associated protein light chain 3-associated phagocytosis in infected RAW 264.7 cells, leading to elevated levels of intracellular killing. The bsaS deletion mutant is highly attenuated for virulence in BALB/c mice | Burkholderia pseudomallei |